RxDoctor Payments Data

Wilfredo Gonzalez, MD

Internal Medicine · Doral, FLNPI 1518074558

Payments from drug & device makers

$5,538in general payments, 2019–2025

Across 82 payments — averaging $67.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Sanofi-aventis U.S. LLC$335
  • Johnson & Johnson$192
  • Amarin Pharma, Inc.$181
  • Novo Nordisk$167
  • Pfizer$93
  • plus $538 from 12 others

What the payments were for

  • Consulting fees$3,60065%
  • Food & beverage$1,92335%
  • Education$150%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,538 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,578
Medicare patients
40
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$34,975
MounjaroTirzepatide30$34,213
TradjentaLinagliptin16$24,963
Synjardy XrEmpagliflozin/Metformin Hcl17$23,057
JanuviaSitagliptin Phosphate17$22,924
OzempicSemaglutide19$17,114
EliquisApixaban17$16,323
VascepaIcosapent Ethyl21$12,409
XareltoRivaroxaban13$9,205
Rosuvastatin Calcium242$3,232
Atorvastatin Calcium205$1,560
Levothyroxine Sodium159$1,371
Diclofenac Sodium37$1,046
Famotidine43$994
Losartan Potassium132$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$32$82,99455 claims
Lilly USA, LLCMounjaro$32$34,21330 claims
MerckJanuvia$59$22,92417 claims
Novo NordiskOzempic$167$17,11419 claims
PfizerEliquis$93$16,32317 claims
Johnson & JohnsonXarelto$192$9,20513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Doral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →